Effect of combined therapy with ephedrine and hyperbaric oxygen on neonatal hypoxic-ischemic brain injury.
Perinatal hypoxic-ischemic (HI) is a major cause of brain injury in the newborn, and there is a lack of effective therapies to reduce injury-related disorders. The aim of the present study was to evaluate the effect of a combination of ephedrine and hyperbaric oxygen (HBO) on neonatal hypoxic-ischemic brain injury. 7-day-old Sprague-Dawley rat pups were randomly divided into sham operation, HI, ephedrine, HBO, and combined group. The ephedrine group was intraperitoneally injected with ephedrine, HBO group was treated for 2h at 2.5 absolute atmosphere (ATA) per day, the combined group received both ephedrine and HBO treatments, the sham operation and HI groups were intraperitoneally injected with normal saline. Rat brains at 7 days after HI, were collected to determine histopathological damage and the expression levels of Caspase-3 and Nogo-A. Four weeks after insult, animals were challenged with Morris water maze test. The expressions of Caspase-3 and Nogo-A were reduced in treating groups compared to those in HI group (P<0.01). Compared with the single treatment groups, the expression levels of Caspase-3 and Nogo-A were significantly reduced in the combined group (P<0.01). Compared with the single treatment groups, the average time of escape latency was significantly shorter (P<0.01) and the number of platform location crossing was more (P<0.05) in combined group. These findings indicate that the combination of ephedrine and HBO can enhance the neuroprotective effect in the neonatal rat HI model partially mediated by inhibiting Caspase-3 and Nogo-A pathways.
Chen
Siyuan
S
Department of Rehabilitation Center, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
Xiao
Nong
N
Zhang
Xiaoping
X
D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D053148:Caspase 3 / Q000378:metabolism; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004809:Ephedrine / Q000008:administration & dosage / Q000494:pharmacology*; D006931:Hyperbaric Oxygenation; D020925:Hypoxia-Ischemia, Brain / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D009185:Myelin Proteins / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000070798:Nogo Proteins; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D009185:Myelin Proteins; D018696:Neuroprotective Agents; D000070798:Nogo Proteins; C000603197:Rtn4 protein, rat; C505410:Casp3 protein, rat; D053148:Caspase 3; D004809:Ephedrine